reports
- Pedro Fonseca
RTW Biotech Opportunities - Termination of coverage
Edison Investment Research is terminating coverage on RTW Biotech Opportunities (RTW). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant...
Edison Investment Research Limited Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets 01-Nov-2023 / 10:51 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 1 November 2023 Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed...
- Pedro Fonseca
RTW Biotech Opportunities - Significant acquisition of Arix Bioscience...
On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed Arix Bioscience in an all-share transaction, which on a pro-forma basis would increase RTWBIO’s NAV by c $550m (c 63%). The deal brings the prospects of increased liquidity in RTWBIO’s shares and a more efficient cost base, and potential for a higher RTWBIO valuation. Arix’s shareholders would receive ne...
- Pedro Fonseca
RTW Biotech Opportunities - Use of Prometheus Biosciences’ sale procee...
In June 2023, RTW Biotech Opportunities (RTWBIO) changed its name from RTW Venture Fund to more accurately reflect the company’s full life cycle approach to biotech investing. On 5 July 2023, RTWBIO announced its capital allocation plans for the proceeds received from Merck’s acquisition of Prometheus Biosciences which, when announced, was the company’s largest holding at 14.8% of NAV. The acquisition price was a 75.4% premium to the pre-bid level. Prometheus is a good example of RTW’s long-term...
- Pedro Fonseca
RTW Venture Fund Limited - Finding value in the out-of-favour biotech ...
RTW Venture Fund (RTWVF) is focused on innovative biotech and medtech businesses that have clear pathways to delivering approved medicines and medical technologies to patients. It is managed by RTW Investments (RTW), a New York-headquartered, life sciences investment firm with offices in London and Shanghai. RTW takes a science-led, full-lifecycle approach to investing in both public and private opportunities, supporting companies at all stages of development via multiple capital solutions. Biot...
- Pedro Fonseca
RTW Venture Fund Limited - Acquisition of largest holding at healthy p...
On Sunday 16 April 2023, US major pharma company Merck (NYSE: MRK) announced that, through a subsidiary, it had entered into a definitive agreement to acquire Prometheus Biosciences (NASDAQ: RXDX) for $200 per share for a total cost of c $10.8bn. At 31 March 2023, Prometheus was RTW Venture Fund’s (RTWVF’s) largest holding at c 14.8% of NAV. The bid price represents a 75.4% premium to Prometheus’s closing price on Friday 14 April, therefore the deal, all else being equal, should represent a mate...
- Pedro Fonseca
RTW Venture Fund Limited - Positive newsflow from major fund holding
RTW Venture Fund (RTWVF) is managed by global healthcare specialist RTW Investments (RTW). It has announced that on 7 December 2022 portfolio company Prometheus Biosciences (NASDAQ: RXDX, cap $4.9bn) reported positive data on two of its clinical trials. At 31 October 2022, which is the date of RTWVF’s last published NAV, Prometheus was its third-largest holding, making up c 7.5% of the fund. This company’s share price rose by 165.7% on 7 December and by a further 22.4% on 8 December (despite the...
- Pedro Fonseca
RTW Venture Fund Limited - Major biotech drawdown providing opportunit...
RTW Venture Fund (RTWVF) is managed by global healthcare specialist RTW Investments (RTW) that has offices in New York, London and Shanghai. It offers a broad range of financing options from business formations through to listed biotech and medtech companies. RTW’s managers are hopeful that the performance of biotech stocks will continue to improve following a significant sell off, particularly in smaller-cap stocks, between February 2021 and May 2022. Biotech industry fundamentals and valuation...
- Pedro Fonseca
RTW Venture Fund Limited - Sector drawdown providing exciting opportun...
RTW Venture Fund (RTWVF) is managed by healthcare specialist RTW Investments (RTW). It has a lifecycle approach to investment, from business formations through to listed biotech and medtech companies. The biotech sector has been under significant pressure since February 2021; small-cap names in particular have sold off, which RTW’s founding partner Dr Roderick Wong believes is providing ‘exciting’ opportunities for RTWVF in 2022. Seeking to take advantage of investing across the globe, rather th...
Edison Investment Research Limited: RTW Venture Fund (RTW) - Initiatio...
Edison Investment Research Limited Edison Investment Research Limited: RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment 12-Jan-2022 / 08:05 GMT/BST London, UK, 12 January 2021 RTW Venture Fund (RTW) - Initiation: 'One-stop shop' for biotech lifecycle investment RTW Venture Fund (RTWVF) is managed by healthcare specialist RTW Investments (RTW), which was founded in 2009 by Dr Roderick Wong. It has an innovative approach, focusing on attractive individual assets rather than on companies, so it engages across the corporate lifecycle, from bu...
- Pedro Fonseca
RTW Venture Fund Limited - ‘One-stop shop’ for biotech lifecycle inves...
RTW Venture Fund (RTWVF) is managed by healthcare specialist RTW Investments (RTW), which was founded in 2009 by Dr Roderick Wong. It has an innovative approach, focusing on attractive individual assets rather than on companies, so it engages across the corporate lifecycle, from business formations through to investing in much larger listed biotech and medtech companies. RTW is focused on identifying and developing next-generation therapies to significantly improve patients’ lives. Since launch,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.